http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Anderson Junger Teodoro,Carolina de Oliveira Ramos Petra de Almeida,Raquel Martins Martinez,Vanessa Rosse de Souza,Thuane Passos Barbosa Lima,Bruna Almeida Nascimento,Gabriel de Alcantara Noblat,Giova 한국식품영양과학회 2024 Journal of medicinal food Vol.27 No.1
This study evaluates the effects of supplementation of murici (Byrsonima crassifolia) and tapereba´ (Spondiasmombin) pulp extracts on dietary intake, body composition, biochemical parameters, and markers of oxidative stress. Twoexperiments were conducted with a total of 80 healthy male Wistar rats and a 30-day supplementation. In the first experiment,animals were divided into control (C) group, murici group 50 mg/(kg$day) (50Mu), murici group 100 mg/(kg$day) (100Mu),and murici group 200 mg/(kg$day) (200Mu). In the second experiment, animals were divided into C group, tapereba´ group50 mg/(kg$day) (50Tap), tapereba´ group 100 mg/(kg$day) (100Tap), and tapereba´ group 200 mg/(kg$day) (200Tap). Resultsshowed lower feed intake in 50Mu, 100Mu, and 100Tap groups (13%, 12%, and 10%, respectively, P < .05) and lower bodyfat in 200Mu, 100Tap, and 200Tap groups (16.0%, 29.1%, and 27.1%, respectively, P < .05). Only the 100Tap group showedreduced adipose tissue content (30.4%; P < .05). Increased plasma antioxidant capacity was observed at all doses for bothfruits. Tapereba´ supplementation reduced ferrous oxidation–xylenol orange levels (50Tap: 8.4%, 100Tap: 16.1%, 200Tap:24.3%; P < .05) and increased thiol levels (50Tap: 39%, 100Tap: 31%; P < .05). Serum thiobarbituric acid reactive substanceslevels were reduced in all groups receiving tapereba´ (50Tap: 77.7%, 100Tap: 73.1%, 200Tap: 73.8%; P < .05) and murici(50Mu: 44.5%, 100Mu: 34%, 200Mu: 43%; P < .05). Therefore, it is suggested that the inclusion of these fruits in the diet cancontribute to health maintenance and disease prevention, through their effects on controlling food intake, improving bodycomposition, and in combating oxidative stress.
( Christoph Sarrazin ),( Curtis L. Cooper ),( Michael P. Manns ),( Rajender Reddy ),( Kris Kowdley ),( Sooji Lee ),( Hadas Dvory-Sobol ),( Evguenia Svarovskia ),( Ross Martin ),( Gregory Camus ),( Bri 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: The pangenotypic combination of sofosbuvir (SOF) /velpatasvir (VEL)/voxilaprevir(VOX), inhibit distinct HCV targets, the NS5B polymerase, the NS5A protein, and NS3/4A protease, respectively. In Phase 3 studies, SOF/VEL/VOX administered for 12weeks demonstrated a 96% SVR12 rate in NS5A inhibitor-experienced patients in POLARIS-1, and a 97% SVR12 rate in DAA-experienced patient who had not previously received an NS5A inhibitor in POLARIS-4. Here, we evaluate the effect of baseline resistance associated substitutions (RASs) on treatment outcome and the emergence of RASs in patients who experienced virologic failure. Methods: NS3, NS5A, and NS5B deep sequencing was performed at baseline for all patients and at the time of virologic failure. NS3 and NS5A class RASs as well as VOX or VEL-specific RASs that confer >2.5-fold changes in EC50 were evaluated. Results: In POLARIS-1, 79% of NS5A inhibitor-experienced patients (205/260) had baseline NS3 and/or NS5A class RASs. Of these, 75% (196/260) had baseline NS5A RASs, the most common RASs. The SVR12 rates were similar in subjects with or without NS3 and/or NS5A class RASs, and with or without VOX or VEL-specific RASs(Table 1). RASs at NS5A position Y93 were present in 25% of patients, of whom 63(95%) achieved SVR12; all patients with ≥2 NS5A RASs achieved SVR12 (n=77). 95%(18/19) of patients with NS5B nucleoside inhibitor(NI) RASs achieved SVR12; 2 patients had S282T at baseline and achieved SVR12. In POLARIS-4, the overall prevalence of baseline NS3 and/or NS5A class RASs was 47%(83/178) and all achieved SVR12. All patients with. Conclusions: Baseline RASs had no impact on response in DAA-experienced patients following treatment with SOF/VEL/VOX for 12 weeks. Viral relapse was not associated with emergence of viral resistance.